GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
-4%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.26B
AUM Growth
-$362M
(-7.8%)
Cap. Flow
-$2.11M
Cap. Flow
% of AUM
-0.05%
Top 10 Holdings %
Top 10 Hldgs %
43.71%
Holding
683
New
46
Increased
475
Reduced
93
Closed
17
Top Buys
| 1 |
Philip Morris
PM
|
$43M |
| 2 |
Amazon
AMZN
|
$24.3M |
| 3 |
Palantir
PLTR
|
$16.8M |
| 4 |
Yum China
YUMC
|
$14.4M |
| 5 |
Hims & Hers Health
HIMS
|
$10.9M |
Top Sells
| 1 |
Pinduoduo
PDD
|
$40.6M |
| 2 |
NVIDIA
NVDA
|
$25.7M |
| 3 |
KE Holdings
BEKE
|
$14.3M |
| 4 |
Meta Platforms (Facebook)
META
|
$13.3M |
| 5 |
Coca-Cola
KO
|
$9.83M |
Sector Composition
| 1 | Technology | 42.51% |
| 2 | Consumer Discretionary | 16.26% |
| 3 | Communication Services | 14.17% |
| 4 | Healthcare | 7.8% |
| 5 | Consumer Staples | 6.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALMS
601
Alumis Inc. Common Stock
ALMS
$479M
| $7.2K | ﹤0.01% |
1,172
+180
| +18% | +$1.11K |
|
602
Alpha Teknova
TKNO
$227M
| $7.08K | ﹤0.01% |
1,365
+246
| +22% | +$1.28K |
|
603
Vanda Pharmaceuticals
VNDA
$274M
| $6.85K | ﹤0.01% |
1,493
+269
| +22% | +$1.24K |
|
604
Prime Medicine
PRME
$606M
| $6.68K | ﹤0.01% |
3,358
+658
| +24% | +$1.31K |
|
|
TECX
605
Tectonic Therapeutic, Inc. Common Stock
TECX
$323M
| $6.68K | ﹤0.01% |
377
+67
| +22% | +$1.19K |
|
606
Aquestive Therapeutics
AQST
$612M
| $6.56K | ﹤0.01% |
2,262
+348
| +18% | +$1.01K |
|
607
Personalis
PSNL
$451M
| $6.35K | ﹤0.01% |
1,809
+326
| +22% | +$1.14K |
|
|
SLRN
608
DELISTED
ACELYRIN
SLRN
| $6.35K | ﹤0.01% |
2,569
+462
| +22% | +$1.14K |
|
|
TSVT
609
DELISTED
2seventy bio
TSVT
| $6.32K | ﹤0.01% |
1,280
+197
| +18% | +$973 |
|
610
Atea Pharmaceuticals
AVIR
$264M
| $6.27K | ﹤0.01% |
2,096
+323
| +18% | +$966 |
|
|
CBL
611
CBL Properties
CBL
$975M
| $6.14K | ﹤0.01% |
231
+9
| +4% | +$239 |
|
612
Amylyx Pharmaceuticals
AMLX
$887M
| $6.02K | ﹤0.01% |
1,700
+261
| +18% | +$924 |
|
613
Terns Pharmaceuticals
TERN
$618M
| $6K | ﹤0.01% |
2,174
+391
| +22% | +$1.08K |
|
614
Coinbase
COIN
$78.8B
| $5.86K | ﹤0.01% |
34
-11
| -24% | -$1.9K |
|
615
Ironwood Pharmaceuticals
IRWD
$179M
| $5.84K | ﹤0.01% |
3,971
+611
| +18% | +$898 |
|
616
Humacyte
HUMA
$231M
| $5.62K | ﹤0.01% |
3,295
+610
| +23% | +$1.04K |
|
617
Design Therapeutics
DSGN
$348M
| $5.59K | ﹤0.01% |
1,449
+260
| +22% | +$1K |
|
|
ITOS
618
DELISTED
iTeos Therapeutics
ITOS
| $5.58K | ﹤0.01% |
935
+168
| +22% | +$1K |
|
619
Codexis
CDXS
$218M
| $5.43K | ﹤0.01% |
2,019
+310
| +18% | +$834 |
|
620
Olema Pharmaceuticals
OLMA
$436M
| $5.35K | ﹤0.01% |
1,422
+219
| +18% | +$823 |
|
621
Annexon
ANNX
$236M
| $5.27K | ﹤0.01% |
2,729
+491
| +22% | +$948 |
|
622
Foghorn Therapeutics
FHTX
$305M
| $5.2K | ﹤0.01% |
1,424
+257
| +22% | +$938 |
|
623
Corvus Pharmaceuticals
CRVS
$427M
| $5.07K | ﹤0.01% |
1,594
+245
| +18% | +$779 |
|
624
Inhibrx
INBX
$402M
| $5.02K | ﹤0.01% |
359
+55
| +18% | +$769 |
|
625
Y-mAbs Therapeutics
YMAB
$389M
| $4.92K | ﹤0.01% |
1,111
+171
| +18% | +$758 |
|